SELLAS Life Sciences (SLS) Short term Debt (2013 - 2018)
SELLAS Life Sciences (SLS) posted quarterly Short term Debt of $76000.0 for Q3 2018, down 99.38% year-over-year from $12.2 million in Q3 2017, and down 99.02% quarter-over-quarter from $7.8 million in Q2 2018.
SELLAS Life Sciences (SLS) Short term Debt (2013 - 2018) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Short term Debt for 6 consecutive years, with $76000.0 the latest figure, recorded in Q3 2018.
- In Q3 2018, Short term Debt fell 99.38% year-over-year to $76000.0; the TTM figure through Sep 2018 stood at $76000.0 (down 99.38% YoY), while the FY2017 annual figure was $8.4 million, up 390.17% from the prior year.
- Short term Debt declined to $76000.0 in Q3 2018 per SLS's latest filing, from $7.8 million in the prior quarter.
- Across five years, Short term Debt topped out at $23.7 million in Q3 2016 and bottomed at $76000.0 in Q3 2018.
- Historically, Short term Debt has averaged $7.7 million across 5 years, with a median of $4.2 million in 2015.
- Annual changes were most pronounced in 2014 — Short term Debt jumped 1254.15% — and 2018, when it sank 99.38%.
- SELLAS Life Sciences' Short term Debt stood at $3.9 million in 2014, then increased by 21.2% to $4.7 million in 2015, then plunged by 63.94% to $1.7 million in 2016, then surged by 390.17% to $8.4 million in 2017, then tumbled by 99.09% to $76000.0 in 2018.
- Business Quant data shows SLS's Short term Debt at $76000.0 in Q3 2018, $7.8 million in Q2 2018, and $8.5 million in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 76,000.00 |
| Jun 30, 2018 | 7.78 Mn |
| Mar 31, 2018 | 8.53 Mn |
| Dec 31, 2017 | 8.38 Mn |
| Sep 30, 2017 | 12.17 Mn |
| Jun 30, 2017 | 13.03 Mn |
| Mar 31, 2017 | 12.60 Mn |
| Dec 31, 2016 | 1.71 Mn |
| Sep 30, 2016 | 23.72 Mn |
| Jun 30, 2016 | 23.16 Mn |
| Mar 31, 2016 | 3.74 Mn |
| Dec 31, 2015 | 4.74 Mn |
| Sep 30, 2015 | 4.17 Mn |
| Jun 30, 2015 | 4.08 Mn |
| Mar 31, 2015 | 3.99 Mn |
| Dec 31, 2014 | 3.91 Mn |
| Sep 30, 2014 | 4.16 Mn |
| Jun 30, 2014 | 4.08 Mn |
| Mar 31, 2014 | 3.10 Mn |
| Dec 31, 2013 | 2.15 Mn |